Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents
Gilles Lemesle [Orateur] (1), Rebecca Torguson (2), Laurent Bonello (3), Cedric Delhaye (1), Augusto Pichard (2), Ron Waksman (2) (1) CHRU Cardiologie, Centre Hémodynamique, Lille, Washington Hospital Center, Washington DC, AP-HM, CHU Nord, Marseille, France Aims: Clopidogrel discontinuation after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation has been reported to correlate with stent thrombosis. Whether these events are a consequence of the rebound phenomenon or a lack of protection in unhealed vessels is unclear. This study aimed to determine the link between clopidogrel cessation and cardiovascular events after PCI with DES. Methods and results: The population included 1,903 patients who underwent PCI with DES implantation from 2003 to 2007. We compared patients who stopped their clopidogrel within the first month (group 1, n=97), from one to six months (group 2, n=344), from six to 12 months (group 3, n=468), and after 12 months (group 4, n=994) following the PCI. In each group, the composite of death, myocardial infarction and stent thrombosis at 30 days and between 31 and 60 days after clopidogrel cessation was indexed. Baseline characteristics were similar among groups. The event rate observed in the 0-30 day interval following cessation was higher only in group 1 (5.2%) compared to all other groups: 1.2% (group 2), 0.9% (group 3) and 0.6% (group 4) (p=0.004). The event rates from 31 to 60 days following cessation were low and similar among the four groups. When the elapsed time between the index PCI and the clopidogrel cessation was analysed as a continuous variable, the probability of events occurring within the first 30 days became similar to that observed in the 31-60 day interval following cessation after a minimum of 10.2 months.
Conclusions:
Cardiac events seen immediately after clopidogrel cessation are not related to a rebound phenomenon, but are more likely influenced by the lack of healing at the time of cessation, which decreases over time. This increased risk related to the lack of healing seems to disappear after 10.2 months.
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One-year outcome of everolimus vs. paclitaxel-eluting stents for the treatment of unprotected left main lesions Anouska Moynagh [Orateur] (1), Neus Salvatella (1), Olivier Darremont (2), Thierry Lefèvre (1), Didier Carrié (3), Yves Louvard (1), Jean-Louis Leymarie (2), Bernard Chevalier (1), Marie-Claude Morice (1), Philippe Garot(1) (1) Institut Hospitalier Jacques Cartier, Institut Cardiovasculaire Paris Sud, Massy, France -(2) Clinique Saint-Augustin, Bordeaux, France -(3) CHU Rangueil, Toulouse, France Background: Coronary artery bypass surgery is recognised as the "gold standard" treatment for unprotected left main (LM) stenosis. However, advances in percutaneous coronary intervention techniques and the introduction of drug eluting stents have led to the acceptance of PCI as an alternative strategy for complex lesions including LM lesions.
Methods:
We performed a matched comparison of patients in the French Left Main Taxus registry and the Left Main Xience registry undergoing unprotected LM stenting with Taxus paclitaxel-eluting (PES) and Xience sirolimus-eluting (SES) stents respectively, in 4 French centres. 172 patients were matched according to Syntax score, stenosis involving the distal LM, provisional side-branch T-stenting and use of one stent in the distal LM.
Results: Patients were aged 69.5±11.3 years, 76.5 % of patients were male. 25.3% of patients were diabetics and 27.3% had undergone previous PCI. Mean Syntax score was 25.5±9.6. The distal LM was involved in 82% and provisional SB T-stenting was performed in 91.1%.
The one-year follow-up results are shown in Table 1 .
Patients were stratified according to the 3 SYNTAX score subgroups. Patients with low SYNTAX score had similar outcomes for MACE at 1 year (9.6% vs. 6.8%, p=0.67) for PES and EES respectively. Intermediate and high Cardiac death was higher in patients with an intermediate SYNTAX score in PES patients (6.8% vs.0.0%, p=0.04) as was TVMI (8.5% vs. 0.0%, p=0.02).
Conclusion:
Unprotected LM stenting with EES is feasible, safe and more effective in the mid term, than with PES with a reduction in MACE, TLF and cardiac death at one year. Objectives: The PACS-HIV study is designed to evaluate the 3-year prognosis of acute coronary syndrome (ACS) in HIV-infected patients (HIV+) as compared to HIV-uninfected patients (HIV-) in a prospective observational study. We aim to present the long term 3-year follow-up.
Methods:
We enrolled consecutively 103 HIV-infected and 195 HIV-uninfected patients with a first episode of ACS matched for age (± 5 years), sex, and type of ACS. The primary endpoint was the rate of major adverse cardiac and cerebral events (MACCE), comprising cardiac death, recurrent ACS, recurrent coronary revascularization, and stroke.
Results:
The mean age of the cohort was 49.0 ± 9.4 years and 94% were men. At baseline, coronary risk factors were well balanced and angiographic features were not different between both groups. MACCE at 3-year are depicted in Table. The rate of occurrence of first MACCE at 36-months was similar in both groups (uivariate hazard ratio [HR]=1.4, 95% CI, 0.7-2.6). However, recurrent ACS was more frequent in HIV+ group as compared with 95% CI, . Stratified multivariate Cox model showed that the only factor associated with the recurrence of ACS was HIV status with HR 7.86 for HIV+ versus HIV-(95% CI, 1.2-50.6, p= 0.03).
Conclusion:
HIV-infected patients had higher recurrence of ACS despite similar coronary risk factors, clinical, and angiographic features at baseline of a first episode of ACS as compared to HIV-uninfected patients. Specific secondary prevention may be warranted to alleviate this risk. Purpose: Our aim was to assess the long term prognosis value of resting HR in a contemporary large cohort of subjects with known CAD.
Methods: Among 834 consecutive male pts hospitalized in 2001-2004 for coronary artery disease, HR was measured in 778 pts. The median follow-up was 7.17 years. Total mortality was predicted with a Cox proportional hazard model Results: Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic, mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean blood pressure was 139 (20) / 84 (11) mmHg. Mean HDL cholesterol was 43 mg/dl (11), mean LDL cholesterol124 mg/dl (39) and median triglycerides were 147 mg/dl IQR . Mean Cockcroft-Gault creatinine clearance was 87 ml/min and 11 pts (1.4%) had a severe chronic renal failure (lower than 30 ml/min). Mean left ventricular ejection fraction was 0.53 (0.13). 88.5% were on antiplatelet therapy, 75.2% on beta-blocker, 66% on statin therapy and 54.8% on ACE inhibitors or ARB. 40.5% of pts had HR < 60 bpm, 32% HR between 60 and 69 bpm and 27.5% had HR t70 bpm. The cumulative seven-year total mortality rate was 17.8%. In the HR < 60 bpm group, mortality rate was 11.1%, whereas it was 17.3% in the group with HR -60 bpm and < 70 bpm and 28.5% in the HR t70 bpm group (p<.001).
We performed a multivariate analysis adjusted for age, diabetes, tobacco consumption (none; d40 pack-years; > 40 pack-years), left ventricular ejection fraction (>0.5; d0.5 and > 0.35; d0.35), duration of CAD, ankle-brachial index (> 0.9; d0.9 and > 0.6; d0.6), history of chronic obstructive pulmonary disease or stroke, statin therapy and coronary revascularization. For every 5 bpm increase in resting heart rate, there was a significant 11% increase in all-cause death (95% CI [4%; 18%] p=0.002).
HR is a strong and independent long term predictor factor of all-cause death in CAD. A close control of HR should be promoted to improve long term prognosis in coronary pts.
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